DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Tracker of 7 GLP-1-class candidates in active development. Phase status, expected FDA timeline, weight-loss data, and manufacturer.
Weight-loss data: ~22.7% mean weight loss at 68 weeks (REDEFINE-1, 2024 readout)
Subcutaneous weekly injection. REDEFINE-1 weight-loss data underperformed prior expectations (had been guided to ~25%). Novo investor sentiment dampened, but FDA approval still expected. Will compete with Zepbound.
Weight-loss data: ~24% mean weight loss at 48 weeks (Phase 2, 2023). Highest reported for any GLP-1-class candidate.
Subcutaneous weekly injection. Triple-agonist mechanism is novel: glucagon component drives liver-mediated lipolysis. Could surpass Zepbound on efficacy. Phase 3 TRIUMPH program enrolling.
Weight-loss data: ~14.7% mean weight loss at 36 weeks (Phase 2 for obesity)
First small-molecule oral GLP-1. Manufacturable at scale (chemical synthesis vs. peptide), potentially cheaper than injectables. No food/water restrictions. Lower efficacy than injectables but adherence benefits significant.
Weight-loss data: ~17% mean weight loss at 68 weeks (OASIS-1)
Higher dose (50 mg) oral semaglutide formulated for weight loss. Existing Rybelsus is 14 mg for T2D. Pill burden (empty stomach, 30 min before food) is the main adherence trade-off. Approval expected 2026.
Weight-loss data: ~19% mean weight loss at 46 weeks (Phase 2)
Weekly injection. Glucagon-arm specifically targets fatty liver (MASH) in parallel with obesity. Phase 3 program ongoing 2025-2027.
Weight-loss data: ~15% mean weight loss at 48 weeks (Phase 3 China)
Chinese-developed candidate. Approval pathway: China first, then likely Eli Lilly or Pfizer partnership for US. Most relevant to US market if Eli Lilly partners.
Weight-loss data: ~15.6% mean weight loss at 48 weeks (Phase 2, IMPACT trial)
MASH-focused candidate. Weight loss is secondary to liver fat reduction. Phase 3 launch pending late 2025.
Editorial summary, updated quarterly. Phase progression, trial readouts, and FDA timelines shift; this is not a regulatory filing schedule. Last reviewed by LoseLab editorial 2026-05-26.